Fiscal Period | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|
Period End Date | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
Revenue | 0.23 | 0.06 | 0.09 | 0.17 |
Total Revenue | 0.23 | 0.06 | 0.09 | 0.17 |
Costof Revenue Total | 0.00 | 0.07 | -0.05 | 0.06 |
Gross Profit | 0.23 | -0.01 | 0.13 | 0.11 |
Selling/ General/ Admin Expenses Total | 0.31 | 0.30 | 0.29 | 0.25 |
Depreciation/ Amortization | 0.09 | 4.95 | 9.92 | 9.91 |
Other Operating Expenses Total | 0.54 | 0.74 | 0.31 | 0.39 |
Total Operating Expense | 0.94 | 6.06 | 10.47 | 10.60 |
Operating Income | -0.71 | -6.00 | -10.39 | -10.44 |
Interest Inc( Exp) Net- Non- Op Total | -1.29 | -1.81 | -2.27 | -2.66 |
Other Net | 0.18 | 0.18 | 0.21 | 0.27 |
Net Income Before Taxes | -0.66 | -6.01 | -10.40 | -10.43 |
Provisionfor Income Taxes | 0.00 | 0.00 | 0.00 | - |
Net Income After Taxes | -0.66 | -6.01 | -10.40 | -10.43 |
Net Income Before Extra Items | -0.66 | -6.01 | -10.40 | -10.43 |
Net Income | -0.66 | -6.01 | -10.40 | -10.43 |
Income Availableto Com Excl Extra Ord | -0.66 | -6.01 | -10.40 | -10.43 |
Income Availableto Com Incl Extra Ord | -0.66 | -6.01 | -10.40 | -10.43 |
Diluted Net Income | -0.66 | -6.01 | -10.40 | -10.43 |
Diluted Weighted Average Shares | 7.28 | 7.58 | 7.58 | 7.58 |
Diluted EPS Excluding Extra Ord Items | -0.09 | -0.79 | -1.37 | -1.38 |
Diluted Normalized EPS | -0.09 | -0.79 | -1.37 | -1.38 |
Gain( Loss)on Saleof Assets | - | 0.00 | 0.00 | 0.00 |
Transgene Biotek Dividend Transgene Biotek Bonus Transgene Biotek News Transgene Biotek AGM Transgene Biotek Rights Transgene Biotek Splits Transgene Biotek Board Meetings Transgene Biotek Key Metrics Transgene Biotek Shareholdings Transgene Biotek Balance Sheet Transgene Biotek Cashflow Transgene Biotek Q1 Results Transgene Biotek Q2 Results Transgene Biotek Q3 Results Transgene Biotek Q4 Results
Top GainersTop LosersIndian IndicesBSE Active StocksNSE Active Stocks